TrialThe Lancet. Neurology2020

Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.

Anthony Traboulsee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.